Wells Fargo 2024 Industrials Conference
Logotype for Corteva Inc

Corteva (CTVA) Wells Fargo 2024 Industrials Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Corteva Inc

Wells Fargo 2024 Industrials Conference summary

1 Feb, 2026

Key achievements and financial performance

  • Celebrated five years as a public company, adding 7,000 patents and improving EBITDA margins by over 500 basis points to 19.6% from 2019 to 2023.

  • Returned over $5 billion to shareholders through dividends and share buybacks since IPO.

  • 2024 EBITDA guidance remains at $3.5–$3.7 billion, with cash flow conversion targeted at 50% of EBITDA.

  • First half EBITDA expected to be 80% of full year, with some shift of crop protection revenue from Q2 to Q3 due to weather delays.

  • Cost savings of $350–$450 million expected in 2024, driven by royalty reductions, productivity, and input cost deflation.

Market and operational updates

  • Strong seed business performance in the U.S., with corn and soybean planting near historic averages despite weather challenges.

  • Crop protection business faces demand-supply imbalances and weather-related delays in both the U.S. and Europe, shifting some sales to later quarters.

  • Latin America impacted by Brazil flooding and Argentina corn stunt, but effects on upcoming season remain uncertain.

  • U.S. corn acreage down about 5% year-over-year, soybeans up, both tracking USDA expectations.

  • Yield expectations remain healthy, with early indicators positive for both corn and soybeans.

Strategic initiatives and future outlook

  • Ongoing focus on controlling costs, with royalty expense reductions expected to make the company royalty neutral by decade's end.

  • Crop protection business to benefit from $150 million tailwind in input cost deflation in 2H 2024.

  • Seed cost benefits expected to materialize in 2025–2026, supporting margin growth.

  • Key drivers for 2025 margin targets include seed pricing, new hybrids, new crop protection products, and growth in the biologicals business.

  • Capital allocation balanced between dividends, share buybacks, and reinvestment, with $1 billion in buybacks targeted for 2024.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more